Publications by authors named "Julius Matasi"

Claim this Profile
I
Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
W Michael Seganish, William T McElroy, R Jason Herr, Stephanie Brumfield, William J Greenlee, Julius Matasi

Bioorg Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.
W Michael Seganish, Thierry O Fischmann, Brad Sherborne, Julius Matasi, Brian Lavey

ACS Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain.
Shu-Wei Yang, Ginny D Ho, Deen Tulshian, Ana Bercovici, Zheng Tan, Julius Matasi

Bioorg Med Chem Lett· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrrolo-benzo-1,4-diazines as potent Na(v)1.7 sodium channel blockers.
Ginny D Ho, Deen Tulshian, Ana Bercovici, Zheng Tan, Jennifer Hanisak, Julius Matasi

Bioorg Med Chem Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain.
Stephanie Brumfield, Peter Korakas, Lisa S Silverman, Deen Tulshian, Julius J Matasi

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2.
Stephanie Brumfield, Julius J Matasi, Deen Tulshian, Michael Czarniecki, William Greenlee

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1.
Julius J Matasi, Stephanie Brumfield, Deen Tulshian, Michael Czarnecki, William Greenlee

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.
Shu-Wei Yang, Jennifer Smotryski, Julius Matasi, Ginny Ho, Deen Tulshian

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2.
John P Caldwell, Julius J Matasi, Xiomara Fernandez, Robbie L McLeod, Hongtao Zhang

Bioorg Med Chem Lett· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
Geoffrey B Varty, Sherry X Lu, Cynthia A Morgan, Mary E Cohen-Williams, Robert A Hodgson, Julius Matasi

J Pharmacol Exp Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.
John P Caldwell, Julius J Matasi, Hongtao Zhang, Ahmad Fawzi, Deen B Tulshian

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists.
Lisa S Silverman, John P Caldwell, William J Greenlee, Eugenia Kiselgof, Julius J Matasi

Bioorg Med Chem Lett· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
Julius J Matasi, John P Caldwell, Hongtao Zhang, Ahmad Fawzi, Mary E Cohen-Williams

Bioorg Med Chem Lett· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
Julius J Matasi, John P Caldwell, Hongtao Zhang, Ahmad Fawzi, Guy A Higgins

Bioorg Med Chem Lett· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.
Julius J Matasi, John P Caldwell, Jinsong Hao, Bernard Neustadt, Leyla Arik

Bioorg Med Chem Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis